Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENLIGHTEN: POSLUMA PET/CT in Biochemically Recurrent Prostate Cancer
NCT06813898Phase 1Recruiting
- Sponsor
- Northwestern University
- Start
- Apr 2025
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of flotufolastat f 18 in prostate cancer (PCa), sponsored by Northwestern University. Primary endpoint: Consensus detection rate by flotufolastat F-18 gallium-PET scan at 2 years. Started Apr 2025; status: recruiting.
02
Drugs
flotufolastat f 18
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT06813898.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06813898.